Can the response to a single dose of beclomethasone dipropionate predict the outcome of long-term treatment in childhood exercise-induced bronchoconstriction?


Journal

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
ISSN: 1399-3038
Titre abrégé: Pediatr Allergy Immunol
Pays: England
ID NLM: 9106718

Informations de publication

Date de publication:
06 2022
Historique:
revised: 09 05 2022
received: 02 02 2022
accepted: 13 05 2022
entrez: 27 6 2022
pubmed: 28 6 2022
medline: 29 6 2022
Statut: ppublish

Résumé

Exercise-induced bronchoconstriction (EIB) is a frequent and highly specific symptom of childhood asthma. Inhaled corticosteroids (ICS) are the mainstay of controller therapy for EIB and asthma; however, a proportion of asthmatic children and adolescents is less responsive to ICS. We hypothesized that a single dose response to ICS could function as a predictor for individual long-term efficacy of ICS. To assess the predictive value of the bronchoprotective effect of a single-dose beclomethasone dipropionate (BDP) against EIB for the bronchoprotective effect of 4 weeks of treatment, using an exercise challenge test (ECT). Thirty-two steroid-naïve children and adolescents aged 6 to 18 years with EIB were included in this prospective cohort study. They performed an ECT at baseline, after a single-dose BDP (200µg) and after 4 weeks of BDP treatment (100 µg twice daily) to assess EIB severity. The response to a single-dose BDP on exercise-induced fall in FEV1 showed a significant correlation with the response on exercise-induced fall in FEV1 after 4 weeks of BDP treatment (r = .38, p = .004). A reduction in post-exercise fall in FEV1 of more than 8% after a single-dose BDP could predict BDP efficacy against EIB after 4 weeks of treatment with a positive predictive value of 100% (CI: 86.1-100%) and a negative predictive value of 29.4% (CI: 11.7%-53.7%). We found that the individual response to a single-dose BDP against EIB has a predictive value for the efficacy of long-term treatment with BDP. This could support clinicians in providing personalized management of EIB in childhood asthma.

Sections du résumé

BACKGROUND
Exercise-induced bronchoconstriction (EIB) is a frequent and highly specific symptom of childhood asthma. Inhaled corticosteroids (ICS) are the mainstay of controller therapy for EIB and asthma; however, a proportion of asthmatic children and adolescents is less responsive to ICS. We hypothesized that a single dose response to ICS could function as a predictor for individual long-term efficacy of ICS.
OBJECTIVE
To assess the predictive value of the bronchoprotective effect of a single-dose beclomethasone dipropionate (BDP) against EIB for the bronchoprotective effect of 4 weeks of treatment, using an exercise challenge test (ECT).
METHODS
Thirty-two steroid-naïve children and adolescents aged 6 to 18 years with EIB were included in this prospective cohort study. They performed an ECT at baseline, after a single-dose BDP (200µg) and after 4 weeks of BDP treatment (100 µg twice daily) to assess EIB severity.
RESULTS
The response to a single-dose BDP on exercise-induced fall in FEV1 showed a significant correlation with the response on exercise-induced fall in FEV1 after 4 weeks of BDP treatment (r = .38, p = .004). A reduction in post-exercise fall in FEV1 of more than 8% after a single-dose BDP could predict BDP efficacy against EIB after 4 weeks of treatment with a positive predictive value of 100% (CI: 86.1-100%) and a negative predictive value of 29.4% (CI: 11.7%-53.7%).
CONCLUSION
We found that the individual response to a single-dose BDP against EIB has a predictive value for the efficacy of long-term treatment with BDP. This could support clinicians in providing personalized management of EIB in childhood asthma.

Identifiants

pubmed: 35754119
doi: 10.1111/pai.13808
doi:

Substances chimiques

Beclomethasone KGZ1SLC28Z

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e13808

Informations de copyright

© 2022 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Références

Global initiative for Asthma. Global Strategy for Asthma Management and Prevention [Internet]. 2021. Available from: www.ginasthma.org
Hallstrand TS, Curtis JR, Aitken ML, Sullivan SD. Quality of life in adolescents with mild asthma. Pediatr Pulmonol. 2003;36(6):536-543.
Brasholt M, Baty F, Bisgaard H. Physical activity in young children is reduced with increasing bronchial responsiveness. J Allergy Clin Immunol. 2010;125(5):1007-1012.
Kojima N, Ohya Y, Futamura M, et al. Exercise-induced asthma is associated with impaired quality of life among children with asthma in Japan. Allergol Int. 2009;58(2):187-192.
Bossley CJ, Fleming L, Ullmann N, et al. Assessment of corticosteroid response in pediatric patients with severe asthma by using a multidomain approach. Journal of Allergy and Clinical Immunology. 2016;138(2):413-420.e6.
Pruteanu AI, Chauhan BF, Zhang L, Prietsch SOM, Ducharme FM. Inhaled corticosteroids in children with persistent asthma: dose-response effects on growth. Cochrane Database Syst Rev. 2014(7):CD009878.
Zhang L, Lasmar LB, Castro-Rodriguez JA. The impact of asthma and its treatment on growth: an evidence-based review. J Pediatr (Rio J). 2019;95(Suppl 1):10-22.
Axelsson I, Naumburg E, Prietsch SO, Zhang L. Inhaled corticosteroids in children with persistent asthma: effects of different drugs and delivery devices on growth. Cochrane Database Syst Rev. 2019;2019(6):CD010126.
Petersen R, Agertoft L, Pedersen S. Treatment of exercise-induced asthma with beclomethasone dipropionate in children with asthma. Eur Respir J. 2004;24(6):932-937.
Kerrebijn KF, van Essen-Zandvliet EEM, Neijens HJ. Effect of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma. J Allergy Clin Immunol. 1987;79(4):653-659.
Szefler SJ, Phillips BR, Martinez FD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. Journal of Allergy and Clinical Immunology. 2005;115(2):233-242.
Zeiger R, Szefler S, Phillips B, et al. Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. Journal of Allergy and Clinical Immunology. 2006.
Drazen JM, Silverman EK, Lee TH. Heterogeneity of therapeutic responses in asthma. Br Med Bull. 2000;56(4):1054-1070.
Barnes PJ, Woolcock AJ. Difficult asthma. Eur Respir J. 1998;12(5):1209-1218.
Stempel DA, Fuhlbrigge AL. Defining the responder in asthma therapy. J Allergy Clin Immunol. 2005;115(3):466-469.
Adcock IM, Ito K. Steroid resistance in asthma: a major problem requiring novel solutions or a non-issue? Curr Opin Pharmacol. 2004;4(3):257-262.
Adcock IM, Lane SJ. Corticosteroid-insensitive asthma: molecular mechanisms. J Endocrinol. 2003;178(3):347-355.
Busse WW, Banks-Schlegel S, Wenzel SE. Pathophysiology of severe asthma. J Allergy Clin Immunol. 2000;106(6):1033-1042.
Duong-Thi-Ly H, Nguyen-Thi-Thu H, Nguyen-Hoang L, Nguyen-Thi-Bich H, Craig TJ, Duong-Quy S. Effects of genetic factors to inhaled corticosteroid response in children with asthma: a literature review. J Int Med Res. 2017;45(6):1818-1830.
Adcock IM, Lane SJ. MECHANISMS OF STEROID ACTION AND RESISTANCE IN INFLAMMATION Corticosteroid-insensitive asthma: molecular mechanisms. J Endocrinol. 2003;178(3):347-355.
Szefler SJ, Martin RJ, King TS, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol. 2002;109(3):410-418.
Licari A, Manti S, Castagnoli R, et al. Immunomodulation in pediatric asthma. Front Pediatr. 2019;7:289.
Manti S, Leonardi S, Parisi GF, et al. High mobility group box 1: biomarker of inhaled corticosteroid treatment response in children with moderate-severe asthma. Allergy Asthma Proc. 2017;38(3):197-203.
Sonntag HJ, Filippi S, Pipis S, Custovic A. Blood biomarkers of sensitization and asthma. Front Pediatrics. 2019;7:251.
Fitzpatrick AM, Jackson DJ, Mauger DT, et al. Individualized therapy for persistent asthma in young children. J Allergy Clin Immunol. 2016;138(6):1608-1618.
Thio BJ, Slingerland GLM, Nagelkerke AF, Roord JJ, Mulder PGH, Dankert-Roelse JE. Effects of single-dose fluticasone on exercise-induced asthma in asthmatic children: a pilot study. Pediatr Pulmonol. 2001;32(2):115-121.
Luijk B, Kempsford RD, Wright AM, Zanen P, Lammers JWJ. Duration of effect of single-dose inhaled fluticasone propionate on AMP-induced bronchoconstriction. Eur Respir J. 2004;23(4):559-564.
Kippelen P, Larsson J, Anderson SD, et al. Acute effects of beclomethasone on hyperpnea-induced bronchoconstriction. Med Sci Sports Exerc. 2010;42(2):273-280.
Ketchell RI, Jensen MW, Lumley P, Wright AM, Allenby MI, O’Connor BJ. Rapid effect of inhaled fluticasone propionate on airway responsiveness to adenosine 5′-monophosphate in mild asthma. J Allergy Clin Immunol. 2002;110(4):603-606.
Visser R, Wind M, de Graaf B, de Jongh FHC, van der Palen J, Thio BJ. Protective effect of a low single dose inhaled steroid against exercise induced bronchoconstriction. Pediatr Pulmonol. 2015;50(12):1178-1183.
Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004;113(1):59-65.
Liu AH, Zeiger R, Sorkness C, et al. Development and cross-sectional validation of the Childhood Asthma Control Test. J Allergy Clin Immunol. 2007;119(4):817-825.
Loeb JS, Blower WC, Feldstein JF, Koch BA, Munlin AL, Hardie WD. Acceptability and repeatability of spirometry in children using updated ATS/ERS criteria. Pediatr Pulmonol. 2008;43(10):1020-1024.
van Leeuwen JC, Driessen JMM, de Jongh FHC, Anderson SD, Thio BJ. Measuring breakthrough exercise-induced bronchoconstriction in young asthmatic children using a jumping castle. J Allergy Clin Immunol. 2013;131(5):1427-1429.e5.
Hallstrand TS, Leuppi JD, Joos G, et al. ERS technical standard on bronchial challenge testing: Pathophysiology and methodology of indirect airway challenge testing. Eur Respir J. 2018;52(5):1801033.
Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319-338.
Anderson SD, Kippelen P. Assessment of EIB: What you need to know to optimize test results. Immunol Allergy Clin North Am. 2013;33(3):pp. 363-80, viii.
Kersten ETG, Akkerman-Nijland AM, Driessen JMM, Diamant Z, Thio BJ. Can a single dose response predict the effect of montelukast on exercise-induced bronchoconstriction? Pediatr Pulmonol. 2016;51(5):470-477.
Visser R, Driessen J, Akkerman AM, van der Palen BJT. Predicting the effect of long term treatment with BDP by a single dose effect: a pilot study. Unpublished manuscript. 2012.
Anderson SD. ‘Indirect’ challenges from science to clinical practice. Eur Clin Respirat J. 2016;3(1):31096
Anderson SD, du Toit JI, Rodwell LT, Jenkins CR. Acute effect of sodium cromoglycate on airway narrowing induced by 4.5 percent saline aerosol: Outcome before and during treatment with aerosol corticosteroids in patients with asthma. Chest. 1994;105(3):673-680.
Ramadan AA, Gaffin JM, Israel E, Phipatanakul W. Asthma and corticosteroid responses in childhood and adult asthma. Clin Chest Med. 2019;40(1):163-177.
Horvath G, Wanner A. Inhaled corticosteroids: effects on the airway vasculature in bronchial asthma. Eur Respir J. 2006;27(1):172-187.
Verrière VA, Hynes D, Faherty S, et al. Rapid effects of dexamethasone on intracellular pH and Na+/H+ exchanger activity in human bronchial epithelial cells. J Biol Chem. 2005;280(43):35807-35814.
Zhou J, Liu D-F, Liu C, et al. Glucocorticoids inhibit degranulation of mast cells in allergic asthma via nongenomic mechanism. Allergy. 2008;63(9):1177-1185.
Perretti M, Ahluwalia A. The microcirculation and inflammation: site of action for glucocorticoids. Microcirculation. 2000;7(3):147-161.
Szefler SJ, Phillips BR, Martinez FD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol. 2005;115(2):233-242.
Zeiger R, Szefler S, Phillips B, et al. Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. Journal of Allergy and Clinical Immunology. 2006;117(1):45-52.
Godfrey S, Springer C, Noviski N, Maayan C, Avital A. Exercise but not methacholine differentiates asthma from chronic lung disease in children. Thorax. 1991;46(7):488-492.
Godfrey S, Springer C, Bar-Yishay E, Avital A. Cut-off points defining normal and asthmatic bronchial reactivity to exercise and inhalation challenges in children and young adults. Eur Respir J. 1999;14(3):659-668.
Godfrey S. What is asthma? Arch Dis Child. 1985;60(11):997-1000.
Balfour-Lynn L, Tooley M, Godfrey S. Relationship of exercise-induced asthma to clinical asthma in childhood. Arch Dis Child. 1981;56(6):450-454.
Weiler JM, Brannan JD, Randolph CC, et al. Exercise-induced bronchoconstriction update-2016. J Allergy Clin Immunol. 2016;138(5):1292-1295.e36.
Jónasson G, Carlsen KH, Hultquist C. Low-dose budesonide improves exercise-induced bronchospasm in schoolchildren. Pediatric Allergy Immunol. 2000;11(2):120-125.
Madhuban AA, Driessen JM, Brusse-Keizer MG, van Aalderen WM, de Jongh FH, Thio BJ. Association of the asthma control questionnaire with exercise-induced bronchoconstriction. J Asthma. 2011;48(3):275-278.
Rapino D, PietroConsilvio N, Scaparrotta A, et al. Relationship between exercise-induced bronchospasm (EIB) and asthma control test (ACT) in asthmatic children. J Asthma. 2011;48(10):1081-1084.
Rapino D, Attanasi M, Consilvio NP, et al. Evaluation of association between airway hyperresponsiveness, asthma control test, and asthma therapy assessment questionnaire in asthmatic children. Multidiscip Respir Med. 2013;8(1):48.
Chinellato I, Piazza M, Sandri M, et al. Evaluation of association between exercise-induced bronchoconstriction and childhood asthma control test questionnaire scores in children. Pediatr Pulmonol. 2012;47(3):226-232.
Haby MM, Peat JK, Mellis CM, Anderson SD, Woolcock AJ. An exercise challenge for epidemiological studies of childhood asthma: Validity and repeatability. Eur Respir J. 1995;8(5):729-736.

Auteurs

Vera S Hengeveld (VS)

Department of Paediatrics, Medisch Spectrum Twente, Enschede, The Netherlands.

Natasja Lammers (N)

Department of Paediatrics, Medisch Spectrum Twente, Enschede, The Netherlands.

Mattienne R van der Kamp (MR)

Department of Paediatrics, Medisch Spectrum Twente, Enschede, The Netherlands.
Department of Biomedical Signals and Systems, University of Twente, Enschede, The Netherlands.

Job van der Palen (J)

Clinical Epidemiology, Medisch Spectrum Twente, Enschede, The Netherlands.
Department of Research Methodology, Measurement and Data Analysis, University of Twente, Enschede, The Netherlands.

Bernard J Thio (BJ)

Department of Paediatrics, Medisch Spectrum Twente, Enschede, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH